Gilead (GILD) shares were up 6% to $47.75 after the close as the Company announced record sales and earnings.
Full Year total Revenues were $7.01B up 31% over 2008.
Full Year Non-GAAP EPS were $3.06 up 40% over 2008.
Fourth Quarter Non-GAAP EPS were $0.93 up 49% over 2008.
Average analysts revenue estimates for 2010 are in the $7.9B range. The Company balance sheet was strengthened now at $3.9B in cash and marketable securities.
The increases were driven primarily by sales of antiviral products for treatment of HIV: Atripla $697.8M and Truvada $2.49B. In 1996 treatment of HIV required 30 pills and now it requires one.
Viread sales also grew to $667.5M for treatment of hepatitis B (HBV).
Full Year Tamiflu royalties from Roche were $392.7M.
Gilead has a strong pipeline of 12 products in the clinic for treatment of HIV,Cystic Fibrosis,HCV and Pulmonary Arterial Hypertension.
GILD is a core holding in the Rayno Life Science Portfolio.
(See additional posts from JPM Conference January 13)